{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:14:03Z","timestamp":1790410443864,"version":"4.1.0"},"reference-count":76,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>The human papillomavirus is one of the most common sexually transmitted viruses, and an infection from this virus may become persistent, leading to diseases such as cervical cancer. In the past, cytology-based methods such as the Papanicolaou (Pap) test were imperative to identify the disease at a stage where it can be treated. However, since the 1980s where the etiological association of HPV and cervical cancer was identified, new tests began emerging directed towards identifying the virus. Furthermore, as the biology of HPV along with the relationships with its host are elucidated, these tests and treatments further advance. Recently in Europe, there is a movement towards the implementation of HPV testing methodologies in national screening programs to precede cytological testing. These screening strategies are recommended by the European guidelines and the World Health Organization. This review presents the current HPV testing methodologies, their application in organized population-based cervical cancer screening programs based on the most recent European guidelines, and their implementation status in countries in Europe.<\/jats:p>","DOI":"10.3390\/life10110290","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T06:23:52Z","timestamp":1605767032000},"page":"290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Methodologies of Primary HPV Testing Currently Applied for Cervical Cancer Screening"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-1588","authenticated-orcid":false,"given":"Andreas C.","family":"Chrysostomou","sequence":"first","affiliation":[{"name":"Department of Biological Sciences, University of Cyprus, 1 University Avenue, Aglantzia, Nicosia 2109, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5340-7109","authenticated-orcid":false,"given":"Leondios G.","family":"Kostrikis","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, University of Cyprus, 1 University Avenue, Aglantzia, Nicosia 2109, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","article-title":"The human papillomavirus family and its role in carcinogenesis","volume":"26","author":"Tommasino","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ogrm.2020.02.003","article-title":"Human papillomavirus","volume":"30","author":"Bowden","year":"2020","journal-title":"Obstet. Gynaecol. Reprod. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2020.02.017","article-title":"High seroprevalence of multiple high-risk human papillomavirus types among the general population of Bonaire, St. Eustatius and Saba, Caribbean Netherlands","volume":"38","author":"Vos","year":"2020","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1016\/j.vaccine.2012.05.089","article-title":"Updating the Natural History of Human Papillomavirus and Anogenital Cancers","volume":"30","author":"Moscicki","year":"2012","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pvr.2018.01.001","article-title":"Redetection of human papillomavirus type 16 infections of the cervix in mid-adult life","volume":"5","author":"Ermel","year":"2018","journal-title":"Papillomavirus Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virusres.2016.12.017","article-title":"The low-risk papillomaviruses","volume":"231","author":"Egawa","year":"2017","journal-title":"Virus Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3389\/fcimb.2020.00234","article-title":"Detection of Alpha, Beta, Gamma, and Unclassified Human Papillomaviruses in Cervical Cancer Samples From Mexican Women","volume":"10","author":"Olszewski","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rantshabeng, P., Kasvosve, I., Ndlovu, A., Gaseitsiwe, S., and Moyo, S. (2019). Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211260"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, J.V., Deluca, G.D., Liotta, D.J., Correa, R.M., Basiletti, J.A., Colucci, M.C., Katz, N., Vizzotti, C., Picconi, M.A., and Giurgiovich, A. (2020). Baseline prevalence and type distribution of Human papillomavirus in sexually active non-vaccinated adolescent girls from Argentina. Rev. Argent. Microbiol.","DOI":"10.1016\/j.ram.2020.06.004"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"Plummer","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3322\/canjclin.45.5.305","article-title":"The current status of the Papanicolaou smear","volume":"45","author":"Shingleton","year":"1995","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00365513.2014.936683","article-title":"HPV and cervical cancer","volume":"74","author":"Petry","year":"2014","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","article-title":"A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions","volume":"80","author":"Durst","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chrysostomou, A., Stylianou, D., Constantinidou, A., and Kostrikis, L. (2018). Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses, 10.","DOI":"10.3390\/v10120729"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000457827","article-title":"Inception and Development of the Papanicolaou Stain Method","volume":"61","author":"Chantziantoniou","year":"2017","journal-title":"Acta Cytol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.2009.1569","article-title":"Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer Precursors: A Randomized Controlled Trial","volume":"302","author":"Siebers","year":"2009","journal-title":"JAMA"},{"key":"ref_18","first-page":"S2","article-title":"The impact of liquid-based cytology in decreasing the incidence of cervical cancer","volume":"4","author":"Gibb","year":"2011","journal-title":"Rev. Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/JOC.JOC_23_16","article-title":"Modified ultrafast Papanicolaou staining technique: A comparative study","volume":"34","author":"Thakur","year":"2017","journal-title":"J. Cytol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000502108","article-title":"A Diagnostic Approach to Endometrial Cytology by Means of Liquid-Based Preparations","volume":"64","author":"Norimatsu","year":"2020","journal-title":"Acta Cytol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Raifu, A.O., El-Zein, M., Sangwa-Lugoma, G., Ramanakumar, A., Walter, S.D., and Franco, E.L. (2017). Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol\u2019s Iodine (VILI) Performed by Nurse and Physician. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170631"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nayar, R., and Wilbur, D.C. (2015). The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes, Springer International Publishing.","DOI":"10.1007\/978-3-319-11074-5"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"h2372","DOI":"10.1136\/bmj.h2372","article-title":"HPV testing as a screen for cervical cancer","volume":"350","author":"Goodman","year":"2015","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bpobgyn.2020.02.008","article-title":"Primary HPV screening for cervical cancer","volume":"65","author":"Bhatla","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ypmed.2016.11.029","article-title":"Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm","volume":"98","author":"Tota","year":"2017","journal-title":"Prev. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination","volume":"1","author":"Arbyn","year":"2015","journal-title":"Papillomavirus Res."},{"key":"ref_27","unstructured":"Von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S., Patnick, J., Ronco, G., Segnan, N., and Suonio, E. (2015). European Guidelines for Quality Assurance in Cervical Cancer Screening\u2014Second Edition Supplements, EU."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bpobgyn.2017.08.012","article-title":"Secondary prevention of cervical cancer","volume":"47","author":"Basu","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s11606-016-3772-5","article-title":"Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years","volume":"31","author":"Jin","year":"2016","journal-title":"J. Gen. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ijgo.12183","article-title":"Management algorithms for cervical cancer screening and precancer treatment for resource-limited settings","volume":"138","author":"Basu","year":"2017","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/CEJ.0000000000000202","article-title":"Present and future of cervical cancer prevention in Spain: A Cost-Effectiveness Analysis","volume":"25","author":"Georgalis","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(18)30536-9","article-title":"Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: A modelling study","volume":"19","author":"Kulasingam","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Hermansson, R.S., Olovsson, M., Hoxell, E., and Lindstr\u00f6m, A.K. (2018). HPV prevalence and HPV-related dysplasia in elderly women. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0189300"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/jcm4050918","article-title":"Current Cervical Carcinoma Screening Guidelines","volume":"4","author":"Schlichte","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cmi.2020.03.033","article-title":"Commercially available molecular tests for human papillomaviruses: A global overview","volume":"26","author":"Poljak","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/erm.2017.2","article-title":"Molecular approaches for HPV genotyping and HPV-DNA physical status","volume":"19","author":"Tsakogiannis","year":"2017","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1566524019666190405120441","article-title":"Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach","volume":"19","author":"Gautam","year":"2019","journal-title":"Curr. Mol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cmi.2015.04.015","article-title":"Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?","volume":"21","author":"Arbyn","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcv.2015.09.014","article-title":"VALGENT: A protocol for clinical validation of human papillomavirus assays","volume":"76","author":"Arbyn","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcv.2018.09.012","article-title":"The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium","volume":"108","author":"Bonde","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cmi.2019.09.006","article-title":"Primary HPV-based cervical cancer screening in Europe: Implementation status, challenges, and future plans","volume":"26","author":"Maver","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_43","unstructured":"PAHO Pan American Health Organization (2020, November 02). Available online: https:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=11925:hpv-tests-for-cervical-cancer-screening&Itemid=41948&showall=1&lang=en."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/14737159.2014.865521","article-title":"cobas \u00ae 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens","volume":"14","author":"Isidean","year":"2014","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.jcv.2015.10.027","article-title":"A review of the clinical performance of the Aptima HPV assay","volume":"76","author":"Haedicke","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Young, S., Vaughan, L., Yanson, K., Eckert, K., Li, A., Harris, J., Ermel, A., Williams, J.A., Al-Ghoul, M., and Cammarata, C.L. (2020). Analytical and Clinical Sample Performance Characteristics of the Onclarity Assay for the Detection of Human Papillomavirus. J. Clin. Microbiol.","DOI":"10.1128\/JCM.02048-20"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1128\/JCM.01743-09","article-title":"Comparison of the Clinical Performance of PapilloCheck Human Papillomavirus Detection with That of the GP5+\/6+-PCR-Enzyme Immunoassay in Population-Based Cervical Screening","volume":"48","author":"Hesselink","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"104336","DOI":"10.1016\/j.jcv.2020.104336","article-title":"Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework","volume":"128","author":"Ejegod","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Snijders, P.J.F., van den Brule, A.J.C., Jacobs, M.V., Pol, R.P., and Meijer, C.J.L.M. (2005). HPV DNA Detection and Typing in Cervical Scrapes. Human Papillomaviruses, Humana Press.","DOI":"10.1385\/1-59259-982-6:101"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.01517-13","article-title":"The Aptima HPV Assay Fulfills the Cross-Sectional Clinical and Reproducibility Criteria of International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening","volume":"51","author":"Heideman","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bonde, J.H., Pedersen, H., Quint, W., Xu, L., Arbyn, M., and Ejegod, D.M. (2020). Clinical and Analytical Performance of the BD Onclarity HPV Assay with Surepath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework. J. Clin. Microbiol., 58.","DOI":"10.1128\/JCM.01518-19"},{"key":"ref_52","unstructured":"Jenkins, D., and Bosch, F.X.B.T.-H.P. (2020). Chapter 7\u2014Developing and Standardizing Human Papillomavirus Tests, Academic Press."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jasc.2019.06.001","article-title":"A Review of the FDA-Approved Molecular Testing Platforms for Human Papillomavirus","volume":"8","author":"Salazar","year":"2019","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","article-title":"Triage of HPV positive women in cervical cancer screening","volume":"76","author":"Wentzensen","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/GMIT.GMIT_56_18","article-title":"Loop electrosurgical excision procedure versus cryotherapy in the treatment of cervical intraepithelialneoplasia: A systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Arduino","year":"2018","journal-title":"Gynecol. Minim. Invasive Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3802\/jgo.2016.27.e3","article-title":"Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: A pooled analysis","volume":"27","author":"Onuki","year":"2016","journal-title":"J. Gynecol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3332\/ecancer.2015.528","article-title":"Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma","volume":"9","author":"Costa","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000507342","article-title":"Comparison Study of Self-Sampled and Physician-Sampled Specimens for High-Risk Human Papillomavirus Test and Cytology","volume":"64","author":"Satake","year":"2020","journal-title":"Acta Cytol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcv.2017.12.008","article-title":"Safety and acceptability of human papillomavirus testing of self-collected specimens: A methodologic study of the impact of collection devices and HPV assays on sensitivity for cervical cancer and high-grade lesions","volume":"99","author":"Leinonen","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e001351","DOI":"10.1136\/bmjgh-2018-001351","article-title":"Self-sampling for human papillomavirus (HPV) testing: A systematic review and meta-analysis","volume":"4","author":"Yeh","year":"2019","journal-title":"BMJ Glob. Health"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"k4823","DOI":"10.1136\/bmj.k4823","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: Updated meta-analyses","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2020.05.006","article-title":"Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France","volume":"81","author":"Lefeuvre","year":"2020","journal-title":"J. Infect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100201","DOI":"10.1016\/j.pvr.2020.100201","article-title":"Corrigendum to \u201cEfficacy of strategies to increase participation in cervical cancer screening: GPs offering self-sampling kits for HPV testing versus recommendations to have a pap smear taken\u2014A randomised controlled trial\u201d [Papillomavirus Res. 9 (2020) 100194]","volume":"9","author":"Peeters","year":"2020","journal-title":"Papillomavirus Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejogrb.2017.01.010","article-title":"The impact on women\u2019s health and the cervical cancer screening budget of primary HPV screening with dual-stain cytology triage in Belgium","volume":"212","author":"Tjalma","year":"2017","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1016\/j.jval.2019.09.240","article-title":"PCN43 new cervical cancer screening policy in germany\u2014what is the impact on the benefit-harm balance?","volume":"22","author":"Sroczynski","year":"2019","journal-title":"Value Health"},{"key":"ref_66","unstructured":"(2020, September 04). Cervical Screening, Available online: https:\/\/deputyprimeminister.gov.mt\/en\/phc\/nbs\/Pages\/Screening-Programmes\/Cervical-Screening.aspx."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jasc.2018.07.003","article-title":"HPV screening, invasive cervical cancer and screening policy in Australia","volume":"7","author":"Cox","year":"2018","journal-title":"J. Am. Soc. Cytopathol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Kong, T.-W., Kim, M., Kim, Y.-H., Kim, Y.B., Kim, J., Kim, J.-W., Park, M.H., Park, J.H., Rhee, J.H., and Lim, M.C. (2020). High-risk human papillomavirus testing as a primary screening for cervical cancer: Position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology. J. Gynecol. Oncol., 31.","DOI":"10.3802\/jgo.2020.31.e31"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ajcp\/aqv019","article-title":"Use of Cytology, E6\/E7 mRNA, and p16 INK4a \u2013Ki-67 to Define the Management of Human Papillomavirus (HPV)\u2013Positive Women in Cervical Cancer Screening","volume":"145","author":"Gustinucci","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41392-019-0081-6","article-title":"Integrative analysis of DNA methylation and gene expression identified cervical cancer-specific diagnostic biomarkers","volume":"4","author":"Xu","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2217\/bmm-2019-0247","article-title":"Discovery of candidate gene expression signatures in peripheral blood for the screening of cervical cancer","volume":"14","author":"Ma","year":"2020","journal-title":"Biomark. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ygyno.2020.07.099","article-title":"Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study","volume":"159","author":"Bao","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ijc.32614","article-title":"FAM19A4\/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study","volume":"147","author":"Vink","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41416-019-0593-4","article-title":"Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): A systematic review and meta-analysis","volume":"121","author":"Kelly","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.2147\/CMAR.S273079","article-title":"Evaluating the Performance of p16INK4a Immunocytochemistry in Cervical Cancer Screening","volume":"12","author":"Song","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1002\/cam4.3296","article-title":"The artificial intelligence-assisted cytology diagnostic system in large-scale cervical cancer screening: A population-based cohort study of 0.7 million women","volume":"9","author":"Bao","year":"2020","journal-title":"Cancer Med."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/10\/11\/290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:34:10Z","timestamp":1760178850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/10\/11\/290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":76,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["life10110290"],"URL":"https:\/\/doi.org\/10.3390\/life10110290","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}